NCT05021900: Efficacy and Safety of Tenalisib (RP6530), a PI3K-Delta-Gamma and SIK3 Inhibitor, in Patients With Locally Advanced or Metastatic Breast Cancer

Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with HER2+ breast cancer; Patients with prior exposure to PI3K inhibitors (e.g. Piqray/alpelisib); Patients with symptomatic uncontrolled brain metastasis

Comments are closed.

Up ↑